Loading...

TruStain FcX™ PLUS (anti-mouse CD16/32) Antibody

Pricing & Availability
Clone
S17011E (See other available formats)
Regulatory Status
RUO
Other Names
CD16, CD32
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
TruStain_FcX_Plus_CD16-CD32_Antibody_122018_updated.png
BALB/c splenocytes were incubated with TruStain FcX™ PLUS (clone S17011E, 0.25µg/106 cells, filled histogram) or TruStain FcX™ (clone 93, 1µg/106 cells, red line histogram) to block the Fc receptors, or were left untreated (black line histogram); then stained with CD90.2 (Thy-1.2, clone 53-2.1) FITC. Note the high background in the untreated cells and the bigger reduction in the background staining when the cells were incubated with TruStain FcX™ Plus compared to TruStain FcX™.
  • TruStain_FcX_Plus_CD16-CD32_Antibody_122018_updated.png
    BALB/c splenocytes were incubated with TruStain FcX™ PLUS (clone S17011E, 0.25µg/106 cells, filled histogram) or TruStain FcX™ (clone 93, 1µg/106 cells, red line histogram) to block the Fc receptors, or were left untreated (black line histogram); then stained with CD90.2 (Thy-1.2, clone 53-2.1) FITC. Note the high background in the untreated cells and the bigger reduction in the background staining when the cells were incubated with TruStain FcX™ Plus compared to TruStain FcX™.
Compare all formats
Cat # Size Price Quantity Check Availability Save
156603 50 µg 52€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
156604 500 µg 221€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD16 is the low affinity IgG Fc receptor III (FcR III) and CD32 is FcR II. CD16/CD32 are expressed on B cells, monocytes/macrophages, NK cells, granulocytes, mast cells, and dendritic cells. The Fc receptors bind antibody-antigen immune complexes and mediate adaptive immune responses. TruStain FcX™ PLUS is specific to the common epitope of CD16/CD32. It is useful for blocking non-specific binding of immunoglobulin to the Fc receptors and is more effective than TruStain FcX™.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Purity
The antibody was purified by affinity chromatography.
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Concentration
0.5 mg/ml
Storage & Handling
The CD16/32 antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
Recommended Usage

For blocking of Fc receptors in flow cytometric analysis, pre-incubate the cells with TruStain FcX™ PLUS for 5-10 minutes, on ice, at 0.25 µg per 106 cells in a volume of 100 µl, prior to immunostaining. It is not necessary to wash the cells between the blocking and immunostaining steps.

Application Notes

Clone S17011E blocks both clone 93 and 2.4G2 also raised against mouse CD16/32

Product Citations
  1. Sugitani N, et al. 2022. Cell Rep. 40:111371. PubMed
  2. Gonzalez C, et al. 2022. Life Sci. 309:121003. PubMed
  3. Egli J, et al. 2022. MAbs. 14:2143009. PubMed
  4. Cai Z, et al. 2023. Adv Sci (Weinh). 10:e2207155. PubMed
  5. Li T, et al. 2023. Adv Sci (Weinh). 10:e2206517. PubMed
  6. Liu HJ, et al. 2023. Nat Commun. 14:1214. PubMed
  7. Sang H, et al. 2023. Adv Clin Exp Med. 32:551. PubMed
  8. Zyla-Jackson K, et al. 2023. Front Neurol. 14:1113954. PubMed
  9. Chen Y, et al. 2023. J Nanobiotechnology. 21:98. PubMed
  10. Gao X, et al. 2023. Front Immunol. 14:1142428. PubMed
  11. Zhou Y, et al. 2023. NPJ Regen Med. 8:23. PubMed
  12. Barisas DAG, et al. 2023. PLoS Biol. 21:e3001746. PubMed
  13. Lee K, et al. 2023. JCI Insight. 8:. PubMed
  14. Lin W, et al. 2023. Commun Biol. 6:447. PubMed
  15. Miyake K, et al. 2023. Nat Commun. 14:2694. PubMed
  16. Wang D, et al. 2023. Nat Commun. 14:2943. PubMed
  17. Arora S, et al. 2023. PLoS One. 18:e0286211. PubMed
  18. Oh J, et al. 2023. Nat Commun. 14:3278. PubMed
  19. Zhou J, et al. 2021. J Immunother Cancer. 9:. PubMed
  20. Driscoll J, et al. 2021. Curr Protoc. 1:e249. PubMed
  21. Bruno MEC, et al. 2022. J Cell Physiol. 237:706. PubMed
  22. Sweeney-Ambros AR, et al. 2022. J Orthop Res. 40:2843. PubMed
  23. Sugimoto M, et al. 2022. DNA Res. 29: . PubMed
  24. Wu J, et al. 2023. Bioact Mater. 20:259. PubMed
  25. Campisi L, et al. 2022. Nature. 606:945. PubMed
  26. Sugimoto S, et al. 2022. Nat Metab. 4:775. PubMed
  27. Li L, et al. 2022. J Exp Med. 219: . PubMed
  28. Wang X, et al. 2022. Sci Adv. 8:eabn0071. PubMed
  29. Chen Y, et al. 2023. Adv Healthc Mater. 12:e2202085. PubMed
  30. Zhu H, et al. 2023. Clin Transl Radiat Oncol. 38:138. PubMed
  31. Dutt TS, et al. 2022. Cell Rep. 41:111783. PubMed
  32. Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed
  33. Cagle LA, et al. 2023. Front Physiol. 13:1059686. PubMed
  34. Lin J, et al. 2023. Nat Commun. 14:224. PubMed
  35. Tanaka T, et al. 2023. Nat Immunol. 24:439. PubMed
  36. Chun J, et al. 2023. Cancers (Basel). 15: . PubMed
  37. Miller CL, et al. 2022. Cell Chem Biol. 29:451. PubMed
  38. Bian L, et al. 2022. Front Immunol. 13:938598. PubMed
  39. Thomas AM, et al. 2022. J Neuroinflammation. 19:130. PubMed
  40. Fu R, et al. 2020. Sci Rep. 10:1455. PubMed
  41. Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed
  42. Toomer G, et al. 2022. Viruses. 14:. PubMed
  43. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  44. Greenberg J, et al. 2022. JCI Insight. Online ahead of print. PubMed
  45. Oliva Chávez AS, et al. 2021. Nat Commun. 12:3696. PubMed
  46. Music A, et al. 2022. Front Cell Dev Biol. 10:987148. PubMed
  47. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  48. Geng T, et al. 2022. Methods Mol Biol. 2585:71. PubMed
  49. Chen X, et al. 2022. J Appl Oral Sci. 30:e20220316. PubMed
  50. Westphal A, et al. 2017. J Exp Med. 214:227. PubMed
  51. Ikeda S, et al. 2022. Sci Rep. 12:11564. PubMed
  52. Thinard R, et al. 2022. Pharmaceutics. 14:. PubMed
  53. So EY, et al. 2021. Am J Physiol Cell Physiol. 321:C569. PubMed
  54. Wang JC, et al. 2022. Elife. 11:. PubMed
  55. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  56. Zeng W, et al. 2021. STAR Protocols. 2(1):100361. PubMed
  57. Dong L, et al. 2022. Cells. 11:. PubMed
  58. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  59. Ejima R, et al. 2021. Nutrients. 13:. PubMed
  60. Oguri Y, et al. 2020. Cell. 182(3):563-577.e20. PubMed
  61. Guo S, et al. 2021. Sci Rep. 11:23745. PubMed
  62. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  63. Galani IE, et al. 2022. STAR Protoc. 3:101151. PubMed
  64. Olson B, et al. 2021. Brain Behav Immun. 97:102. PubMed
  65. Grubiši? V, et al. 2020. Cell Rep. 32:108100. PubMed
  66. Montel-Hagen A, et al. 2022. Curr Protoc. 2:e403. PubMed
  67. Chen AF, et al. 2022. Nat Methods. 19:547. PubMed
  68. Chakraborty M, et al. 2021. Cell Reports. 34(2):108609. PubMed
  69. Li N, et al. 2022. Nat Commun. 13:7281. PubMed
  70. Chen S, et al. 2022. iScience. 25:105176. PubMed
  71. Oya Y, et al. 2021. Front Immunol. 12:779709. PubMed
  72. Hobbs BE, et al. 2021. Pathogens. 10:. PubMed
  73. Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed
  74. Fan ZP, et al. 2021. Front Immunol. 12:743354. PubMed
  75. Phan TS, et al. 2021. Sci Adv. 7:. PubMed
  76. Casselli T, et al. 2021. PLoS Pathog. 17:e1009256. PubMed
  77. Rocha-Resende C, et al. 2020. JCI Insight. 5:00. PubMed
  78. Kos S, et al. 2019. PLoS One. 14:e0217762. PubMed
  79. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  80. Madsen CS, et al. 2022. Commun Biol. 5:888. PubMed
  81. Liu Q, et al. 2021. Adv Mater. 33:e2102852. PubMed
  82. Van Winkle JA, et al. 2020. J Virol. 94:. PubMed
  83. Beyer AI, et al. 2017. Stem Cells Dev. 26:102. PubMed
  84. Wang Y, et al. 2021. Nature. 599:308. PubMed
  85. Wang X, et al. 2021. Sci Transl Med. 13:. PubMed
  86. Gardner A, et al. 2022. J Immunother Cancer. 10:. PubMed
  87. Xu L, et al. 2022. Front Immunol. 13:841141. PubMed
  88. Matsuda A, et al. 2020. J Appl Toxicol. 40:706. PubMed
  89. Celias DP, et al. 2022. STAR Protoc. 3:101464. PubMed
  90. Badgujar DC, et al. 2020. PLoS Pathog. 16:e1009016. PubMed
RRID
AB_2783137 (BioLegend Cat. No. 156603)
AB_2783137 (BioLegend Cat. No. 156604)

Antigen Details

Structure
Ig superfamily, 40-60 kD
Distribution

B cells, monocyte/macrophages, NK cells, neutrophils, mast cells, dendritic cells

Ligand/Receptor
IgG
Cell Type
B cells, Dendritic cells, Macrophages, Mast cells, Monocytes, Neutrophils, NK cells
Biology Area
Immunology
Molecular Family
CD Molecules, Fc Receptors
Gene ID
14130 View all products for this Gene ID 14131 View all products for this Gene ID
UniProt
View information about CD16/32 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 2    Revision Date: 01.22.2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account